Ancillary Treatment versus Co-Amoxiclav in Bacterial  Rhinosinusitis Management

Shahid Iqbal, Ikram Ullah, Muhammad Ali Ranjha, Arshad Abbas, Wajih Ud Din Shinwari, Jamshed Khan

Ancillary Treatment versus Co-Amoxiclav in Bacterial Rhinosinusitis Management

Authors

Shahid Iqbal, Ikram Ullah, Muhammad Ali Ranjha, Arshad Abbas, Wajih Ud Din Shinwari, Jamshed Khan

Keywords:

Acute bacterial rhinosinusitis, co amoxiclav, ancillary therapy, intranasal corticosteroid, nasal irrigation

Abstract

Background: Acute bacterial rhinosinusitis (ABRS) presents a clinical challenge in optimizingmanagement between antibiotic therapy and supportive (ancillary) measures. This studycompares the outcomes of ancillary treatment alone versus antibiotic therapy with Co amoxiclav in adult patients with ABRS

References

Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis in adults and children. Otolaryngol Head Neck Surg. 2004;130(1 Suppl):1-45

Downloads

Published

2025-11-13

How to Cite

Shahid Iqbal, Ikram Ullah, Muhammad Ali Ranjha, Arshad Abbas, Wajih Ud Din Shinwari, Jamshed Khan. (2025). Ancillary Treatment versus Co-Amoxiclav in Bacterial Rhinosinusitis Management . International Journal of Pharmacy Research & Technology (IJPRT), 15(2), 3594–3599. Retrieved from https://www.ijprt.org/index.php/pub/article/view/1247